Loading...

Carmell Therapeutics Corporation

CTCXW•NASDAQ
Healthcare
Biotechnology
$0.03
$-0.02(-45.40%)

Carmell Therapeutics Corporation (CTCXW) Stock Overview

Explore Carmell Therapeutics Corporation’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 66.8/100

Key Financials

Market Cap558.2K
P/E Ratio-0.06
EPS (TTM)N/A
ROE2.47%
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$0.02

CTCXW Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Carmell Therapeutics Corporation (CTCXW) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $0.02.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.06 and a market capitalization of 558.2K. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for CTCXWStats details for CTCXW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for CTCXWAnalyst Recommendations details for CTCXW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.

CEO

Rajiv Sarman Shukla

Employees

9

Headquarters

2403 Sidney Street, Pittsburgh, PA

Founded

1970

Frequently Asked Questions

;